However, during the pathologic changes associated with tumor growth, this prior myeloid priming by Myadm, observed in non-tumor-bearing mT2 mice, could initiate the enhanced MDSC response observed in tumor-bearing mT2 mice. This evidence concerns the gene MYADM and neoplasm.